Your browser doesn't support javascript.
loading
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Shah, Jatin; Shacham, Sharon; Kauffman, Michael; Daniele, Patrick; Tomaras, Dimitrios; Tremblay, Gabriel; Casasnovas, Rene-Olivier; Maerevoet, Marie; Zijlstra, Josee; Follows, George; P Vermaat, Joost S; Kalakonda, Nagesh; Goy, Andre Henri; Choquet, Sylvain; Den Neste, Eric Van; Hill, Brian T; Thieblemont, Catherine; Cavallo, Federica; la Cruz, Fátima de; Kuruvilla, John; Hamad, Nada; Bouabdallah, Reda; Jäger, Ulrich; Caimi, Paolo; Gurion, Ronit; Warzocha, Krzysztof; Bakhshi, Sameer; Sancho, Juan Manuel; Schuster, Michael; Egyed, Miklós; Offner, Fritz; Vasilakopoulos, Theodoros P; Samal, Priyanka; Nagy, Agnes; Ku, Matthew; Canales Albendea, Miguel Ángel.
Affiliation
  • Shah J; Karyopharm Therapeutics, Inc., Newton, MA 02459, USA.
  • Shacham S; Karyopharm Therapeutics, Inc., Newton, MA 02459, USA.
  • Kauffman M; Karyopharm Therapeutics, Inc., Newton, MA 02459, USA.
  • Daniele P; Health Economics, Purple Squirrel Economics, Montreal, QC H3J 1M1, Canada.
  • Tomaras D; Health Economics, Purple Squirrel Economics, Montreal, QC H3J 1M1, Canada.
  • Tremblay G; Health Economics, Purple Squirrel Economics, Montreal, QC H3J 1M1, Canada.
  • Casasnovas RO; Clinical Hematology, CHU Dijon Bourgogne, Dijon, 21079, France.
  • Maerevoet M; Hématologie, Institut Jules Bordet, Brussels, 1000, Belgium.
  • Zijlstra J; Department of Hematology, Amsterdam UMC, Amsterdam, 1105 AZ, The Netherlands.
  • Follows G; Haematology, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
  • P Vermaat JS; Hematology, Leiden University Medical Center, Leiden, 2333 ZA, The Netherlands.
  • Kalakonda N; Institute of Translational Medicine, University of Liverpool, Liverpool, L3 9TA, UK.
  • Goy AH; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
  • Choquet S; Service d'Hématologie clinique, Hôpital Pitié-Salpêtrière, Paris, 75013, France.
  • Den Neste EV; Faculté de médecine et médecine dentaire, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, 1348, Belgium.
  • Hill BT; Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH 44106, USA.
  • Thieblemont C; Hémato-Oncologie, Hôpital Saint-Louis, Paris, 75010, France.
  • Cavallo F; Divisione di Ematologia, University of Turin, Turin, 10138, Italy.
  • la Cruz F; Facultativo Especialista de Área de Hematología, Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain.
  • Kuruvilla J; Cancer Clinical Research Unit, University Health Network Research, Toronto, ON, Canada.
  • Hamad N; Haematology Clinical Trials Unit, St Vincent's Hospital, Melbourne, 3065, Australia.
  • Bouabdallah R; Hematology, Institut Paoli-Calmettes, Marseille, 13009, France.
  • Jäger U; Department of Clinical Hematology & Hemostaseology, Medical University of Vienna, Vienna, 1090, Austria.
  • Caimi P; Department of Medicine, UH Cleveland Medical Center, Cleveland, OH 44106, USA.
  • Gurion R; Hematology, Tel Aviv University, Tel Aviv, 69978, Israel.
  • Warzocha K; Institute of Hematology & Blood Transfusion, Warsaw, 02-776, Poland.
  • Bakhshi S; Department of Medical Oncology, Institute Rotary Cancer Hospital, New Delhi, 110029, India.
  • Sancho JM; Department of Clinical Hematology, Germans Trias i Pujol Hospital, Barcelona, 08916, Spain.
  • Schuster M; Hematology, Stony Brook University, NY 11794, USA.
  • Egyed M; Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvár, 7400, Hungary.
  • Offner F; Department of Clinical Hematology, Ghent University Hospital, Ghent, 9000, Belgium.
  • Vasilakopoulos TP; Faculty of Medicine, National & Kapodistrian University of Athens, Athens, 10679, Greece.
  • Samal P; IMS & SUM Hospital, Bhubaneswar, Odisha, India.
  • Nagy A; Hematology, Semmelweis University, Budapest, 1085, Hungary.
  • Ku M; Department of Haematology, St Vincent's Hospital, Melbourne, VIC, 3065, Australia.
  • Canales Albendea MÁ; Servicio de Hematología, Hospital Universitario La Paz, Madrid, 28046, Spain.
Future Oncol ; 17(11): 1295-1310, 2021 Apr.
Article in En | MEDLINE | ID: mdl-33528286
Lay abstract This work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy ­ Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts. Clinical trial registration: NCT02227251 (ClinicalTrials.gov).
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Lymphoma, Large B-Cell, Diffuse / Hydrazines Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazoles / Lymphoma, Large B-Cell, Diffuse / Hydrazines Type of study: Prognostic_studies Aspects: Patient_preference Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2021 Document type: Article Affiliation country: United States Country of publication: United kingdom